申请人:Kandula Mahesh
公开号:US20150126497A1
公开(公告)日:2015-05-07
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute hypertension or malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications.
该发明涉及式I化合物或其药用可接受的盐,以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括有效量的式I化合物的药物组合物,以及治疗代谢综合征的方法可以制成口服、颊部、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这些组合物可用于治疗急性高血压或恶性高血压、疾病状态下的低血糖,如胰岛素瘤(产生胰岛素的肿瘤)或先天性高胰岛素血症、高尿酸血症、痛风、血脂异常、肥胖、尿素循环紊乱、高血糖、胰岛素抵抗、糖尿病、尿崩症、1型糖尿病、2型糖尿病、微血管并发症、大血管并发症、脂质异常、糖尿病前期、肥胖、心律失常、心肌梗死、中风、神经病变、肾脏并发症、高三酸甘油酯血症和心血管并发症。